Aims: Australian dermatologists are becoming familiar with prescribing dupilumab since it was listed on the PBS on the 1st March 2021. The presentation, management and long-term sequelae of dupilumab-associated ocular surface disease is discussed as outlined in a Nature article.

Methods: We report a case, the clinical findings, and how it was managed by an ophthalmologist. An adolescent male was commenced on dupilumab for his severe atopic dermatitis, having not achieved satisfactory control with topical corticosteroids, phototherapy, and oral methotrexate. Soon after commencing the dupilumab injections, he developed bilateral eye symptoms of photophobia, epiphora, itch and occasional pain. A diagnosis of dupilumab-associated ocular surface disease was confirmed by an ophthalmologist.

Results: This patient discussed in this case report was managed with a combination of steroid and ciclosporin.

Conclusions: Dupilumab-associated ocular surface disease is more common than initially reported. Patients should be educated on this side effect and how to seek help. Evaluation by an ophthalmologist should be sought for patients on dupilumab who develop symptoms of conjunctivitis.